AstraZeneca signs AI drug discovery deal with insitro worth up to $1.86 billion

AstraZeneca has signed a drug discovery collaboration with insitro, the AI-driven biotech, in a deal Bloomberg reported is worth up to $1.86 billion.

The goal is to find new biological targets for two notoriously stubborn disease areas. One is a liver condition most people have never heard of. The other involves the heart muscle itself.

What AstraZeneca is actually paying for

The partnership, announced on October 15, 2026, focuses on metabolic dysfunction-associated steatohepatitis, or MASH. That is the clinical name for an advanced form of fatty liver disease.

The second focus is cardiomyopathies, a group of disorders that affect the heart muscle.

Under the announced terms, AstraZeneca will make an initial payment of $40 million to insitro. On top of that, insitro could collect approximately $1.46 billion tied to discovery, development, and commercial milestones.

insitro would also receive single-digit royalties on global sales of any resulting products.

AstraZeneca keeps exclusive worldwide rights to the intellectual property that comes out of the work. Once insitro’s platform identifies targets, AstraZeneca takes over clinical development and handles regulatory activities.

Investors seemed mildly pleased. AstraZeneca shares saw a modest rise in premarket trading after the announcement.

Inside the Virtual Human platform

The engine behind the deal is insitro’s Virtual Human AI platform. It draws on large volumes of human and cellular data to pinpoint biological targets and push them toward clinical development.

The platform is designed to identify causal disease mechanisms.

MASH and cardiomyopathies are a logical proving ground. Both are marked by heterogeneity, meaning the underlying biology varies widely across patients. Traditional discovery methods have struggled in exactly these conditions.

Part of a bigger pipeline push

The insitro tie-up slots into AstraZeneca’s broader research and development strategy. The company is targeting approximately $80 billion in total revenue and the launch of 20 new medicines by 2030.

For insitro, the deal extends a strategy of building out pharma partnerships around its machine learning capabilities. The company previously expanded its partnership work with Bristol Myers Squibb.

What this means for pharma and AI biotech

The deal structure tells you a lot about how big pharma is approaching AI right now. The $40 million upfront is a small fraction of the headline value. Most of the money is contingent on milestones that may or may not be reached.

AstraZeneca gets access to the platform and full rights to whatever it finds. insitro gets validation, cash in hand, and meaningful upside if its targets survive the long road through clinical trials.